Regulatory T-cells in Psoriasis Patients as Targets for Therapy

Launched by UNIVERSITY OF ABERDEEN · Nov 2, 2010

Keywords

ClinConnect Summary

This is an observational study for the effect of different treatment options of psorisis on regulatory T-cells. Patients in whom a decision to treat with one of the following therapies (Dovobet, neotigason, narrow-band UVB and anti TNF alpha therapy) and agreed to take part in the study will be selected. Allocation of different treatments to patients is not part of the study. We will enroll 40 patients with moderate to severe psoriasis in the age range from 18 to 70. patients must be treatment-free for at least 2 weeks for topical application and 4 weeks for systemic treatment of psoriasis....

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • • Male and female patients in the age range from 18 to 70 who are diagnosed with moderate to severe psoriasis.
• • Patients must be treatment free for at least 2 weeks for topical application and 4 weeks for systemic treatment of psoriasis.
• • Women of child bearing potential must be on reliable contraception.
• * Patients in whom a decision to treat with one of the following therapies has already been made based on normal clinical care:
• • Dovobet
• • Neotigason
• • Narrow-band UVB
• • Etanercept
• • Adalimumab
• • Infliximab
• • 10 normal controls
• Exclusion Criteria:
• • • Children below 18 years and patients over 70 years.
• • Pregnant and lactating patients.
• • Patients who are known to have immunosuppressive disease (e.g. HIV) or on any immunosuppressive therapy.